XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals announces 1-for-4 ADS ratio change [Seeking Alpha]
XTL Biopharmaceuticals Announces ADS Ratio Change
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. [Yahoo! Finance]
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing